科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: Treatment of peritoneal carcinomatosis is a medical challenge. No clear standards exist regarding the medical treatment and the choice of drugs. Method: Relevant publications regarding the aspect of peritoneal carcinomatosis were searched for in the databases of the U.S. National Library of Medicine (PubMed) as well as in the congress databases of the American Society of Clinical Oncology and the European Society of Medical Oncology. The impact of publications on clinical practice was discussed among the authors. Practice-oriented conclusions were drawn and recommendations were delineated. Results: PubMed identified an increasing number of publications. In 2012, 563 publications were listed under the search term %26apos;peritoneal carcinomatosis%26apos;. The medical treatment of peritoneal carcinomatosis is part of the multimodal treatment of peritoneal carcinomatosis and thereby supplements local surgical and physical treatment modalities. The choice of chemotherapy regimens depends on the underlying malignant disease. Current targeted therapies such as anti-angiogenic drugs or immunotherapy against epithelial cell adhesion molecule (EpCAM) expand the treatment options for peritoneal carcinomatosis and malignant ascites. Conclusion: The medical treatment of peritoneal carcinomatosis remains a challenge. However, the increasing number of publications and studies in this field allows for more evidence-based recommendations. The interdisciplinary coordination of an individual treatment concept for every patient remains the gold standard regarding the treatment of peritoneal carcinomatosis.
- 出版日期2013
